Cortisol awakening response in patients with psychosis: Systematic review and meta-analysis

Neuroscience and Biobehavioral Reviews

Volumn 68, Issue , 2016, Pages 157-166

  Berger, Maximus ^a   Kraeuter, Ann Katrin ^a   Romanik, Daria ^b   Malouf, Peter ^a   Amminger, G Paul ^c   Sarnyai, Zoltán ^a  

^a JAMES COOK UNIVERSITY   (Australia)

^b TOWNSVILLE HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CAR; Cortisol; First episode psychosis; HPA axis; Psychosis; Ultra high risk

Indexed keywords

HYDROCORTISONE; NEUROLEPTIC AGENT;

AROUSAL; CORTISOL AWAKENING RESPONSE; HIGH RISK POPULATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; META ANALYSIS; SALIVA;

HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; PSYCHOTIC DISORDERS; SALIVA;

EID: 84971668215     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2016.05.027     Document Type: Review

References (79)

1. Aas M., Dazzan P., Mondelli V., Toulopoulou T., Reichenberg A., Di Forti M., Fisher H.L., Handley R., Hepgul N., Marques T., Miorelli A., Taylor H., Russo M., Wiffen B., Papadopoulos A., Aitchison K.J., Morgan C., Murray R.M., Pariante C.M. Abnormal cortisol awakening response predicts worse cognitive function in patients with first-episode psychosis. Psychol. Med. 2011, 41:463-476.
2. Aiello G., Horowitz M., Hepgul N., Pariante C.M., Mondelli V. Stress abnormalities in individuals at risk for psychosis: a review of studies in subjects with familial risk or with at risk mental state. Psychoneuroendocrinology 2012, 37:1600-1613.
3. Amminger G.P., Schafer M.R., Schlogelhofer M., Klier C.M., McGorry P.D. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat. Commun. 2015, 6:7934.
4. Anacker C., O'Donnell K.J., Meaney M.J. Early life adversity and the epigenetic programming of hypothalamic-pituitary-adrenal function. Dialogues Clin. Neurosci. 2014, 16:321-333.
5. Arnsten A.F.T. Stress signalling pathways that impair prefrontal cortex structure and function. Nat. Rev. Neurosci. 2009, 10:410-422.
6. Barrientos R.M., Thompson V.M., Kitt M.M., Amat J., Hale M.W., Frank M.G., Crysdale N.Y., Stamper C.E., Hennessey P.A., Watkins L.R., Spencer R.L., Lowry C.A., Maier S.F. Greater glucocorticoid receptor activation in hippocampus of aged rats sensitizes microglia. Neurobiol. Aging 2015, 36:1483-1495.
7. Belvederi Murri M., Pariante C.M., Dazzan P., Hepgul N., Papadopoulos A.S., Zunszain P., Di Forti M., Murray R.M., Mondelli V. Hypothalamic-pituitary-adrenal axis and clinical symptoms in first-episode psychosis. Psychoneuroendocrinology 2012, 37:629-644.
8. Bloomfield P.S., Selvaraj S., Veronese M., Rizzo G., Bertoldo A., Owen D.R., Bloomfield M.A., Bonoldi I., Kalk N., Turkheimer F., McGuire P., de Paola V., Howes O.D. Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [C]PBR28 PET brain imaging study. Am. J. Psychiatry 2015, 10.1176/appi.ajp.2015.14101358.
9. Boehringer A., Tost H., Haddad L., Lederbogen F., Wust S., Schwarz E., Meyer-Lindenberg A. Neural correlates of the cortisol awakening response in humans. Neuropsychopharmacology 2015, 40:2278-2285.
10. Brunelin J., d'Amato T., van Os J., Cochet A., Suaud-Chagny M.F., Saoud M. Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls. Schizophr. Res. 2008, 100:206-211.
11. Castro M.N., Villarreal M.F., Bolotinsky N., Papavero E., Goldschmidt M.G., Costanzo E.Y., Drucaroff L., Wainsztein A., de Achaval D., Pahissa J., Bar K.J., Nemeroff C.B., Guinjoan S.M. Brain activation induced by psychological stress in patients with schizophrenia. Schizophr. Res. 2015, 168:313-321.
12. Champagne F.A. Early environments, glucocorticoid receptors, and behavioral epigenetics. Behav. Neurosci. 2013, 127:628-636.
13. Chaumette B., Kebir O., Mam-Lam-Fook C., Morvan Y., Bourgin J., Godsil B.P., Plaze M., Gaillard R., Jay T.M., Krebs M.-O. Salivary cortisol in early psychosis: new findings and meta-analysis. Psychoneuroendocrinology 2016, 63:262-270.
14. Chida Y., Steptoe A. Cortisol awakening response and psychosocial factors: a systematic review and meta-analysis. Biol. Psychol. 2009, 80:265-278.
15. Ciufolini S., Dazzan P., Kempton M.J., Pariante C., Mondelli V. HPA axis response to social stress is attenuated in schizophrenia but normal in depression: evidence from a meta-analysis of existing studies. Neurosci. Biobehav. Rev. 2014, 47c:359-368.
16. Cohrs S., Roher C., Jordan W., Meier A., Huether G., Wuttke W., Ruther E., Rodenbeck A. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology (Berl.) 2006, 185:11-18.
17. Cullen A.E., Zunszain P.A., Dickson H., Roberts R.E., Fisher H.L., Pariante C.M., Laurens K.R. Cortisol awakening response and diurnal cortisol among children at elevated risk for schizophrenia: relationship to psychosocial stress and cognition. Psychoneuroendocrinology 2014, 46:1-13.
18. Day F.L., Valmaggia L.R., Mondelli V., Papadopoulos A., Papadopoulos I., Pariante C.M., McGuire P. Blunted cortisol awakening response in people at ultra high risk of developing psychosis. Schizophr. Res. 2014, 158:25-31.
19. DeSantis A.S., DiezRoux A.V., Hajat A., Aiello A.E., Golden S.H., Jenny N.S., Seeman T.E., Shea S. Associations of salivary cortisol levels with inflammatory markers: the multi-ethnic study of Atherosclerosis. Psychoneuroendocrinology 2012, 37:1009-1018.
20. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
21. Desantis A.S., Kuzawa C.W., Adam E.K. Developmental origins of flatter cortisol rhythms: socioeconomic status and adult cortisol activity. Am. J. Hum. Biol. 2015, 27:458-467.
22. Fillman S.G., Sinclair D., Fung S.J., Webster M.J., Shannon Weickert C. Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder. Transl. Psychiatry 2014, 4:e365.
23. Fillman S.G., Weickert T.W., Lenroot R.K., Catts S.V., Bruggemann J.M., Catts V.S., Weickert C.S. Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca/'s area volume. Mol. Psychiatry 2015, (published online ahead of print, 21 July 2015, http://www.nature.com/mp/journal/vaop/ncurrent/full/mp201590a.html).
24. Frank M.G., Miguel Z.D., Watkins L.R., Maier S.F. Prior exposure to glucocorticoids sensitizes the neuroinflammatory and peripheral inflammatory responses to E. coli lipopolysaccharide. Brain Behav. Immun. 2010, 24:19-30.
25. Fries E., Dettenborn L., Kirschbaum C. The cortisol awakening response (CAR): facts and future directions. Int. J. Psychophysiol. 2009, 72:67-73.
26. Fusar-Poli P., Bonoldi I., Yung A.R., Borgwardt S., Kempton M.J., Valmaggia L., Barale F., Caverzasi E., McGuire P. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch. Gen. Psychiatry 2012, 69:220-229.
27. Fusar-Poli P., Borgwardt S., Bechdolf A., Addington J., Riecher-Rossler A., Schultze-Lutter F., Keshavan M., Wood S., Ruhrmann S., Seidman L.J., Valmaggia L., Cannon T., Velthorst E., De Haan L., Cornblatt B., Bonoldi I., Birchwood M., McGlashan T., Carpenter W., McGorry P., Klosterkotter J., McGuire P., Yung A. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 2013, 70:107-120.
28. Garner B., Pariante C.M., Wood S.J., Velakoulis D., Phillips L., Soulsby B., Brewer W.J., Smith D.J., Dazzan P., Berger G.E., Yung A.R., van den Buuse M., Murray R., McGorry P.D., Pantelis C. Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biol. Psychiatry 2005, 58:417-423.
29. Girshkin L., Matheson S.L., Shepherd A.M., Green M.J. Morning cortisol levels in schizophrenia and bipolar disorder: a meta-analysis. Psychoneuroendocrinology 2014, 49:187-206.
30. Hempel R.J., Tulen J.H., van Beveren N.J., Roder C.H., de Jong F.H., Hengeveld M.W. Diurnal cortisol patterns of young male patients with schizophrenia. Psychiatry Clin. Neurosci. 2010, 64:548-554.
31. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21:1539-1558.
32. Higgins J., Deeks J., Altman D. Special topics in statistics. Cochrane Handbook for Systematic Reviews of Interventions 2011, The Cochrane Collaboration. J. Higgins, S. Green (Eds.).
33. Horowitz M.A., Zunszain P.A., Anacker C., Musaelyan K., Pariante C.M. Glucocorticoids and inflammation: a double-headed sword in depression? How do neuroendocrine and inflammatory pathways interact during stress to contribute to the pathogenesis of depression?. Mod. Trends Pharmacopsychiatry 2013, 28:127-143.
34. Kelly B.D., O'Callaghan E., Waddington J.L., Feeney L., Browne S., Scully P.J., Clarke M., Quinn J.F., McTigue O., Morgan M.G., Kinsella A., Larkin C. Schizophrenia and the city: a review of literature and prospective study of psychosis and urbanicity in Ireland. Schizophr. Res. 2010, 116:75-89.
35. Khandaker G.M., Pearson R.M., Zammit S., Lewis G., Jones P.B. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiatry 2014, 71(10):1121-1128.
36. Kidd T., Carvalho L.A., Steptoe A. The relationship between cortisol responses to laboratory stress and cortisol profiles in daily life. Biol. Psychol. 2014, 99:34-40.
37. Kohrt B.A., Worthman C.M., Ressler K.J., Mercer K.B., Upadhaya N., Koirala S., Nepal M.K., Sharma V.D., Binder E.B. Cross-cultural gene- environment interactions in depression, post-traumatic stress disorder, and the cortisol awakening response: FKBP5 polymorphisms and childhood trauma in South Asia GxE interactions in South Asia. Int. Rev. Psychiatry 2015, 27:180-196.
38. Labad J., Stojanovic-Perez A., Montalvo I., Sole M., Cabezas A., Ortega L., Moreno I., Vilella E., Martorell L., Reynolds R.M., Gutierrez-Zotes A. Stress biomarkers as predictors of transition to psychosis in at-risk mental states: roles for cortisol, prolactin and albumin. J. Psychiatry Res. 2015, 60:163-169.
39. Lederbogen F., Kirsch P., Haddad L., Streit F., Tost H., Schuch P., Wust S., Pruessner J.C., Rietschel M., Deuschle M., Meyer-Lindenberg A. City living and urban upbringing affect neural social stress processing in humans. Nature 2011, 474:498-501.
40. Lipsey M., Wilson D. Practical Meta-Analysis 2000, SAGE Publications Inc, Thousand Oaks, CA. 1 ed.
41. Liston C., Cichon J.M., Jeanneteau F., Jia Z., Chao M.V., Gan W.B. Circadian glucocorticoid oscillations promote learning-dependent synapse formation and maintenance. Nat. Neurosci. 2013, 16:698-705.
42. Lupien S.J., McEwen B.S., Gunnar M.R., Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat. Rev. Neurosci. 2009, 10:434-445.
43. McEwen B.S., Stellar E. Stress and the individual. Mechanisms leading to disease. Arch. Int. Med. 1993, 153:2093-2101.
44. McEwen B.S. Protective and damaging effects of stress mediators. N. Engl. J. Med. 1998, 338:171-179.
45. McEwen B.S. Effects of adverse experiences for brain structure and function. Biol. Psychiatry 2000, 48:721-731.
46. McGorry P., Keshavan M., Goldstone S., Amminger P., Allott K., Berk M., Lavoie S., Pantelis C., Yung A., Wood S., Hickie I. Biomarkers and clinical staging in psychiatry. World Psychiatry 2014, 13:211-223.
47. McGrath J., Saha S., Welham J., El Saadi O., MacCauley C., Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2004, 2:13.
48. Mondelli V., Dazzan P., Hepgul N., Di Forti M., Aas M., D'Albenzio A., Di Nicola M., Fisher H., Handley R., Marques T.R., Morgan C., Navari S., Taylor H., Papadopoulos A., Aitchison K.J., Murray R.M., Pariante C.M. Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment. Schizophr. Res. 2010, 116:234-242.
49. Mondelli V., Ciufolini S., Belvederi Murri M., Bonaccorso S., Di Forti M., Giordano A., Marques T.R., Zunszain P.A., Morgan C., Murray R.M., Pariante C.M., Dazzan P. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophr. Bull. 2015, 41:1162-1170.
50. Monteleone P., Di Filippo C., Fabrazzo M., Milano W., Martiadis V., Corrivetti G., Monteleone A.M., Maj M. Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure. Psychiatry Res. 2014, 215:263-267.
51. Munder T., Brutsch O., Leonhart R., Gerger H., Barth J. Researcher allegiance in psychotherapy outcome research: an overview of reviews. Clin. Psychol. Rev. 2013, 33:501-511.
52. Nordholm D., Krogh J., Mondelli V., Dazzan P., Pariante C., Nordentoft M. Pituitary gland volume in patients with schizophrenia, subjects at ultra high-risk of developing psychosis and healthy controls: a systematic review and meta-analysis. Psychoneuroendocrinology 2013, 38:2394-2404.
53. Pace T.W., Hu F., Miller A.H. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav. Immun. 2007, 21:9-19.
54. Pariante C.M., Pearce B.D., Pisell T.L., Sanchez C.I., Po C., Su C., Miller A.H. The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrinology 1999, 140:4359-4366.
55. Perkins D.O., Jeffries C.D., Addington J., Bearden C.E., Cadenhead K.S., Cannon T.D., Cornblatt B.A., Mathalon D.H., McGlashan T.H., Seidman L.J., Tsuang M.T., Walker E.F., Woods S.W., Heinssen R. Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. Schizophr. Bull. 2015, 41:419-428.
56. Phillips L.J., Velakoulis D., Pantelis C., Wood S., Yuen H.P., Yung A.R., Desmond P., Brewer W., McGorry P.D. Non-reduction in hippocampal volume is associated with higher risk of psychosis. Schizophr. Res. 2002, 58:145-158.
57. Pruessner J.C., Wolf O.T., Hellhammer D.H., Buske-Kirschbaum A., von Auer K., Jobst S., Kaspers F., Kirschbaum C. Free cortisol levels after awakening: a reliable biological marker for the assessment of adrenocortical activity. Life Sci. 1997, 61:2539-2549.
58. Pruessner J.C., Champagne F., Meaney M.J., Dagher A. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride. J. Neurosci. 2004, 24:2825-2831.
59. Pruessner M., Boekestyn L., Bechard-Evans L., Abadi S., Vracotas N., Joober R., Pruessner J.C., Malla A.K. Sex differences in the cortisol response to awakening in recent onset psychosis. Psychoneuroendocrinology 2008, 33:1151-1154.
60. Pruessner M., Vracotas N., Joober R., Pruessner J.C., Malla A.K. Blunted cortisol awakening response in men with first episode psychosis: relationship to parental bonding. Psychoneuroendocrinology 2013, 38:229-240.
61. Pruessner M., Lepage M., Collins D.L., Pruessner J.C., Joober R., Malla A.K. Reduced hippocampal volume and hypothalamus-pituitary-adrenal axis function in first episode psychosis: evidence for sex differences. Neuroimage Clin. 2015, 7:195-202.
62. Raison C.L., Borisov A.S., Woolwine B.J., Massung B., Vogt G., Miller A.H. Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol. Psychiatry 2010, 15:535-547.
63. Ryan M.C., Sharifi N., Condren R., Thakore J.H. Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology 2004, 29:1065-1070.
64. Snyers L., De Wit L., Content J. Glucocorticoid up-regulation of high-affinity interleukin 6 receptors on human epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:2838-2842.
65. Stalder T., Kirschbaum C., Kudielka B.M., Adam E.K., Pruessner J.C., Wust S., Dockray S., Smyth N., Evans P., Hellhammer D.H., Miller R., Wetherell M.A., Lupien S.J., Clow A. Assessment of the cortisol awakening response: expert consensus guidelines. Psychoneuroendocrinology 2016, 63:414-432.
66. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010, 25:603-605.
67. Steinheuser V., Ackermann K., Schonfeld P., Schwabe L. Stress and the city: impact of urban upbringing on the (re)activity of the hypothalamus-pituitary-adrenal axis. Psychosom. Med. 2014, 76:678-685.
68. Stroud L.R., Foster E., Papandonatos G.D., Handwerger K., Granger D.A., Kivlighan K.T., Niaura R. Stress response and the adolescent transition: performance versus peer rejection stressors. Dev. Psychopathol. 2009, 21:47-68.
69. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., Moher D., Becker B.J., Sipe T.A., Thacker S.B. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
70. Sudheimer K., Keller J., Gomez R., Tennakoon L., Reiss A., Garrett A., Kenna H., O'Hara R., Schatzberg A.F. Decreased hypothalamic functional connectivity with subgenual cortex in psychotic major depression. Neuropsychopharmacology 2015, 40:849-860.
71. Thompson K.N., Berger G., Phillips L.J., Komesaroff P., Purcell R., McGorry P.D. HPA axis functioning associated with transition to psychosis: combined DEX/CRH test. J. Psychiatry Res. 2007, 41:446-450.
72. Venkatasubramanian G., Chittiprol S., Neelakantachar N., Shetty T., Gangadhar B.N. Effect of antipsychotic treatment on Insulin-like growth factor-1 and cortisol in schizophrenia: a longitudinal study. Schizophr. Res. 2010, 119:131-137.
73. Walker E.F., Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol. Rev. 1997, 104:667-685.
74. Walker E.F., Trotman H.D., Pearce B.D., Addington J., Cadenhead K.S., Cornblatt B.A., Heinssen R., Mathalon D.H., Perkins D.O., Seidman L.J., Tsuang M.T., Cannon T.D., McGlashan T.H., Woods S.W. Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study. Biol. Psychiatry 2013, 74:410-417.
75. Wallace B., Schmid C., Lau J., Trikalinos T. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med. Res. Methodol. 2009, 9:80.
76. Wilhelm I., Born J., Kudielka B.M., Schlotz W., Wust S. Is the cortisol awakening rise a response to awakening?. Psychoneuroendocrinology 2007, 32:358-366.
77. Witthaus H., Kaufmann C., Bohner G., Ozgurdal S., Gudlowski Y., Gallinat J., Ruhrmann S., Brune M., Heinz A., Klingebiel R., Juckel G. Gray matter abnormalities in subjects at ultra-high risk for schizophrenia and first-episode schizophrenic patients compared to healthy controls. Psychiatry Res. 2009, 173:163-169.
78. Wohleb E.S., McKim D.B., Sheridan J.F., Godbout J.P. Monocyte trafficking to the brain with stress and inflammation: a novel axis of immune-to-brain communication that influences mood and behavior. Front. Neurosci. 2014, 8:447.
79. Yung A.R., McGorry P.D. Prediction of psychosis: setting the stage. Br. J. Psychiatry 2007, Suppl. 51:s1-s8.